Great Point Partners logo

Great Point Partners

North America, Connecticut, United States, Greenwich

Description

The principals of Great Point Partners have a long history of helping executives build successful health care companies.

Investor Profile

Great Point Partners has made 55 investments, with 7 in the past 12 months and 42% as lead.

Stage Focus

  • Post Ipo Equity (65%)
  • Private Equity (16%)
  • Series Unknown (9%)
  • Series A (5%)
  • Debt Financing (2%)
  • Series B (2%)

Country Focus

  • United States (87%)
  • Canada (5%)
  • France (4%)
  • United Kingdom (4%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Biopharma
  • Medical Device
  • Manufacturing
  • Information Technology
  • Clinical Trials
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Great Point Partners frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 5
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Avidity Partners
North America, Texas, United States, Dallas
Co-Investments: 5
RTW Investments
North America, New York, United States, New York
Co-Investments: 5
TCG Crossover
North America, California, United States, Palo Alto
Co-Investments: 5
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 6
Deep Track Capital
North America, Connecticut, United States, Greenwich
Co-Investments: 12
Vivo Capital
North America, California, United States, Palo Alto
Co-Investments: 7
CC
North America, New York, United States, New York
Co-Investments: 6
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 7

What are some of recent deals done by Great Point Partners?

Neurogene

New York, New York, United States

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology
Post Ipo EquityNov 4, 2024
Amount Raised: $200,000,000
Inventiva Pharma

Daix, Bourgogne, France

Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.

BiopharmaBiotechnologyClinical TrialsMedicalMedical Device
Post Ipo EquityOct 14, 2024
Amount Raised: $126,004,765
Cellipont Bioservices

Poway, California, United States

Cellipont Bioservices is a cell therapy CDMO that specializes in cell therapy development and small-to-large batch production.

BiotechnologyHealth CareManufacturingTherapeutics
Series UnknownOct 7, 2024
Oruka Therapeutics

Waltham, Massachusetts, United States

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

BiotechnologyHealth CareMedical
Post Ipo EquitySep 3, 2024
Amount Raised: $275,000,000
ProMIS Neurosciences

Toronto, Ontario, Canada

ProMIS Neurosciences develops therapeutic products and diagnostic devices targeting misfolded protein diseases.

BiotechnologyHealth DiagnosticsMedicalNeuroscienceTherapeutics
Post Ipo EquityJul 26, 2024
Amount Raised: $30,300,000
Context Therapeutics

Philadelphia, Pennsylvania, United States

Context Therapeutics is a clinical-stage biopharmaceutical company.

BiotechnologyHealth Care
Post Ipo EquityMay 2, 2024
Amount Raised: $100,000,000
Zura Bio

San Diego, California, United States

Zura Bio is a clinical-stage biotechnology company that develops medicines for immune system disorders.

BiopharmaBiotechnologyMedical
Post Ipo EquityApr 18, 2024
Amount Raised: $112,500,000
Unicycive Therapeutics

Los Altos, California, United States

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.

BiotechnologyHealth CareHealth DiagnosticsMedical
Post Ipo EquityMar 14, 2024
Amount Raised: $50,000,000
Lexicon Pharmaceuticals

The Woodlands, Texas, United States

Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops precise medicines for human disease.

BioinformaticsBiotechnologyMedicalPharmaceutical
Post Ipo EquityMar 11, 2024
Amount Raised: $250,000,000
MindMed

New York, New York, United States

MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.

BiotechnologyHealth CarePharmaceutical
Post Ipo EquityMar 7, 2024
Amount Raised: $175,000,000